SanegeneBio has secured $200.0 million in new investment, the clinical-stage biotechnology company announced today. This significant capital infusion will support the company's mission to discover and develop best-in-class genetic medicines. Founded in 2021 by industry veterans with deep RNAi expertise, SanegeneBio is focused on leveraging RNA interference (RNAi) technology to address obesity, cardiometabolic, and autoimmune diseases.
The Boston-headquartered company, with R&D operations in both the U.S. and China, specializes in its proprietary LEAD™ (Ligand and Enhancer Assisted Delivery) technology platform. This platform enables tissue-specific silencing of disease-driving genes in various cell types, including liver, adipose tissue, muscle, and immune cells, through safe and infrequent subcutaneous dosing. The successful completion of this funding round underscores investor confidence in SanegeneBio's innovative approach to genetic medicines and its potential to deliver transformative RNAi therapies for conditions with high unmet medical needs.
The newly raised capital will be strategically deployed to advance SanegeneBio's clinical pipeline, accelerate ongoing research and development initiatives, and further scale its proprietary LEAD™ technology platform. These investments are critical as the company progresses its programs aimed at addressing global unmet medical needs and expanding its therapeutic reach. SanegeneBio remains committed to its goal of bringing forward novel genetic medicines that offer significant therapeutic benefits, positioning the company for continued growth and impact in the field of genetic medicine.
.png&w=3840&q=75)
